Trevi Therapeutics (TRVI) financial statements
Net income was -$43M.
Free cash flow was -$42M.
The diluted share count rose 30692% over the period (dilution).
Income statement
Fiscal years, from Trevi Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $14M | $19M | $22M | $23M | $20M | $24M | $39M | $33M |
| Selling, general and admin | $4M | $7M | $10M | $9M | $10M | $10M | $12M | $16M |
| Operating income | -$18M | -$27M | -$32M | -$32M | -$30M | -$34M | -$52M | -$49M |
| Interest expense | $174,000 | — | $456,000 | $1M | $1M | $391,000 | $4,000 | $0 |
| Pre-tax income | -$21M | -$26M | -$33M | -$34M | -$29M | -$29M | -$48M | -$43M |
| Income tax | -$124,000 | -$18,000 | -$18,000 | -$21,000 | -$36,000 | -$32,000 | -$30,000 | -$64,000 |
| Net income | -$21M | -$26M | -$33M | -$34M | -$29M | -$29M | -$48M | -$43M |
| EPS (diluted) | -$58.44 | -$2.28 | -$1.81 | -$1.49 | -$0.45 | -$0.29 | -$0.47 | -$0.32 |
| Diluted shares | 0M | 12M | 18M | 23M | 65M | 99M | 102M | 135M |
Balance sheet
Fiscal years, from Trevi Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $7M | $57M | $45M | $37M | $121M | $83M | $108M | $188M |
| Total current assets | $9M | $60M | $46M | $38M | $123M | $88M | $109M | $192M |
| Property, plant and equipment | $149,000 | $118,000 | $103,000 | $53,000 | $170,000 | $216,000 | $157,000 | $178,000 |
| Total assets | $11M | $60M | $47M | $38M | $123M | $89M | $111M | $193M |
| Total current liabilities | $3M | $5M | $6M | $13M | $13M | $6M | $11M | $10M |
| Total liabilities | $120M | $5M | $20M | $21M | $16M | $7M | $11M | $10M |
| Shareholders' equity | -$109M | $55M | $27M | $17M | $107M | $83M | $100M | $183M |
| Net debt | -$7M | -$57M | -$45M | -$37M | -$13M | -$32M | -$34M | -$19M |
Cash flow
Fiscal years, from Trevi Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18M | -$23M | -$29M | -$29M | -$28M | -$32M | -$38M | -$42M |
| Capital spending | $158,000 | $9,000 | $32,000 | — | $159,000 | $137,000 | $35,000 | $12,000 |
| Free cash flow | -$18M | -$23M | -$29M | — | -$28M | -$32M | -$38M | -$42M |
| Stock-based compensation | $496,000 | $1M | $2M | $3M | $2M | $2M | $4M | $5M |
| Net borrowing | -$5M | — | $14M | — | -$6M | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TRVI.
Open TRVI in InvestinglyQuestions
How much free cash flow does Trevi Therapeutics generate?
-$42M in fiscal 2025 (operating cash flow minus capital spending).
From Trevi Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.